Vitamin B2 & Cancer: Blocking Ferroptosis for New Therapies

The body’s intricate defense systems against cancer are constantly being re-evaluated, and a new study suggests vitamin B2, similarly known as riboflavin, plays a surprisingly central role in protecting tumor cells from a specific type of cell death called ferroptosis. Researchers at the Rudolf Virchow Centre at the University of Würzburg have uncovered a mechanism linking vitamin B2 metabolism to the stability of a protein called FSP1, which is crucial for preventing this iron-dependent form of cellular self-destruction. This discovery, published in Nature Cell Biology on March 13, 2026, could open new avenues for cancer therapies by targeting this metabolic pathway.

Ferroptosis: A Distinct Pathway to Cell Death

Programmed cell death isn’t a single process, but a collection of carefully regulated biological events the body uses to eliminate damaged or dangerous cells. Ferroptosis differs from the more well-known apoptosis. Instead of relying on caspase enzymes, ferroptosis is triggered by iron-dependent oxidative reactions in cell membrane lipids. When oxidized fats accumulate in the cell membrane and antioxidant defenses are overwhelmed, the cell loses structural integrity. This is particularly relevant to cancer research due to the fact that tumors often thrive in environments characterized by high metabolic activity, free radicals, and an imbalanced redox state. Cancer cells develop robust defense mechanisms to evade ferroptosis, and these mechanisms are now being investigated as potential therapeutic targets.

Vitamin B2, a nutrient the human body cannot produce and must obtain through diet from sources like dairy, eggs, meat, and green vegetables, is central to this defense. Within cells, riboflavin is converted into the cofactors FMN and FAD, essential for numerous redox reactions. These molecules support enzymes that transfer electrons, limit oxidative damage, and stabilize metabolism. This connection extends beyond general nutrition into highly specialized cellular processes within mitochondria, membranes, and other cellular compartments.

FSP1 and the Role of Vitamin B2

The study highlights the importance of FSP1, a protein that acts as a shield against ferroptosis. As long as this protective function is intact, even heavily stressed tumor cells can escape membrane damage driven by iron. When FSP1 function is compromised, the balance shifts, making the cell vulnerable to self-destruction. The research team demonstrated that FAD, derived from vitamin B2, isn’t just involved in electron transfer, but also structurally stabilizes FSP1. Without sufficient FAD, the amount of FSP1 decreases, the protein misfolds, and is more readily broken down through the ubiquitin-proteasome pathway. Experiments showed that disrupting riboflavin metabolism significantly weakened the defense against ferroptosis within a 72-hour timeframe.

How the Experiments Unveiled the Connection

The researchers employed a precise approach, using genome editing to disable RFK (riboflavin kinase) or FLAD1 (flavin adenine dinucleotide synthase), enzymes crucial for FMN and FAD production. In the affected cancer cells, FSP1 levels dropped, and sensitivity to GPX4 inhibitors – compounds known to induce ferroptosis – increased dramatically. Markers of lipid peroxidation also rose, further supporting the link to ferroptosis. The team also utilized roseoflavin, a riboflavin analog produced by bacteria, which effectively impaired FSP1 function and triggered ferroptosis even at exceptionally low concentrations (in the nanomolar range). This suggests that targeting the specific part of the riboflavin metabolic pathway that stabilizes FSP1 could be a viable therapeutic strategy. The University of Würzburg’s research page provides further details on these experimental findings.

Why Targeting Ferroptosis Holds Promise for Cancer Treatment

Tumors operate under significant biochemical stress. Rapid cell division demands high energy consumption, leading to increased production of reactive molecules that attack membranes, proteins, and DNA. This makes ferroptosis a particularly attractive target. The process involves iron-dependent reactions oxidizing unsaturated fatty acids in cell membranes, ultimately causing the membrane structure to collapse. Many cancer cells are vulnerable to ferroptosis, but also build strong defense systems. These defenses include enzymes that scavenge lipid radicals, regenerate coenzymes, and limit oxidative damage. Disrupting any of these protective lines can rapidly increase lipid peroxidation and push the cell towards irreversible damage.

A related study, highlighted by Research in Bavaria, also points to the potential of dietary interventions to induce ferroptosis in aggressive cancer cells. While this research is still in its early stages, it underscores the growing interest in harnessing the body’s own cellular processes to fight cancer.

Vital Caveats and What Comes Next

Despite these promising findings, a direct cancer therapy isn’t imminent. The study demonstrates a mechanistic link in cell models, but hasn’t been established in humans. Vitamin B2 is essential for many healthy cells, as its cofactors are involved in numerous metabolic pathways. A blanket withdrawal of the vitamin would be neither sensible nor safe. The focus, instead, is on whether tumors can be selectively targeted at the portion of the riboflavin metabolic pathway that stabilizes FSP1.

Further uncertainties remain. Tumors vary significantly in their biology, not every cancer type relies on FSP1 to the same extent, and results from cell cultures don’t always translate to complex tissues. This research primarily identifies a new vulnerability in tumor metabolism, rather than a ready-to-use treatment. The next steps involve further investigation into the specific mechanisms by which riboflavin metabolism influences FSP1 stability in different cancer types, and exploring the potential for developing targeted therapies that selectively disrupt this pathway without harming healthy cells. Clinical trials will be necessary to determine the safety and efficacy of any such therapies.